Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells

Scientists developed curcumin nanoparticles and evaluated their cytotoxicity in docetaxel (DTX)-resistant castration-resistant prostate cancer (CRPC) cells for the treatment of DTX-resistant CRPC.
[Biomedicines]
Tanaudommongkon, I., Tanaudommongkon, A., Prathipati, P., Nguyen, J. T., Keller, E. T., & Dong, X. (2020). Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells. Biomedicines, 8(8), 253. https://doi.org/10.3390/biomedicines8080253 Cite
Full Article

Continue reading “Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells”

Bookmark

No account yet? Register

0
Share

Predicting New Drug Indications for Prostate Cancer: The Integration of an In Silico Proteochemometric Network Pharmacology Platform with Patient‐Derived Primary Prostate Cells

Researchers integrated a computational proteochemometric systems network pharmacology platform, DrugGenEx‐Net, with primary, continuous cultures of conditionally reprogrammed normal and prostate cancer (PCa) cells derived from treatment‐naive patients with primary PCa.
[Prostate]
Naeem, A., Dakshanamurthy, S., Walthieu, H., Parasido, E., Avantaggiati, M., Tricoli, L., Kumar, D., Lee, R. J., Feldman, A., Noon, M. S., Byers, S., Rodriguez, O., & Albanese, C. (n.d.). Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells. The Prostate, n/a(n/a). https://doi.org/10.1002/pros.24050 Cite
Full Article

Continue reading “Predicting New Drug Indications for Prostate Cancer: The Integration of an In Silico Proteochemometric Network Pharmacology Platform with Patient‐Derived Primary Prostate Cells”

Bookmark

No account yet? Register

0
Share

Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review

Researchers review the current status of immunotherapy, including new discoveries and precision approaches to prostate cancer, and discuss future directions in the continuously evolving landscape of immunotherapy.
[International Journal of Molecular Sciences]
Kim, T. J., & Koo, K. C. (2020). Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review. International Journal of Molecular Sciences, 21(15), 5484. https://doi.org/10.3390/ijms21155484 Cite
Full Article

Continue reading “Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review”

Bookmark

No account yet? Register

0
Share

Chelerythrine Suppresses Proliferation and Metastasis of Human Prostate Cancer Cells via Modulating MMP/TIMP/NF-κB System

The addition of chelerythrine significantly inhibited the proliferation of androgen-independent prostate cancer DU145 and PC-3 cells at the concentration of 5 and 10 μM, but not on androgen-dependent prostate cancer LNCaP cells as well as normal prostate epithelial cell line PrEC cells.
[Molecular and Cellular Biochemistry]
Yang, B., Zhang, D., Qian, J., & Cheng, Y. (2020). Chelerythrine suppresses proliferation and metastasis of human prostate cancer cells via modulating MMP/TIMP/NF-κB system. Molecular and Cellular Biochemistry. https://doi.org/10.1007/s11010-020-03845-0 Cite
Abstract

Continue reading “Chelerythrine Suppresses Proliferation and Metastasis of Human Prostate Cancer Cells via Modulating MMP/TIMP/NF-κB System”

Bookmark

No account yet? Register

0
Share

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

ORIC Pharmaceuticals, Inc. announced it has entered into an exclusive worldwide license agreement with Mirati Therapeutics, Inc. ORIC will have exclusive worldwide rights for the development activities and commercialization of a small molecule allosteric inhibitor program directed towards the polycomb repressive complex 2, a validated oncogenic target across several cancers with promising therapeutic potential in prostate cancer, among other indications.
[ORIC Pharmaceuticals, Inc.]
Press Release

Continue reading “ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics”

Bookmark

No account yet? Register

0
Share

Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice

Scientists determined the effects of grape antioxidants quercetin and/or resveratrol against prostate cancer in the transgenic adenocarcinoma of mouse prostate (TRAMP)-model in prevention and intervention settings.
[Cancers]
Singh, C. K., Chhabra, G., Ndiaye, M. A., Siddiqui, I. A., Panackal, J. E., Mintie, C. A., & Ahmad, N. (2020). Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice. Cancers, 12(8), 2141. https://doi.org/10.3390/cancers12082141 Cite
Full Article

Continue reading “Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice”

Bookmark

No account yet? Register

0
Share

The Spectrum of Design Solutions for Improving the Activity-Selectivity Product of Peptide Antibiotics against Multidrug-Resistant Bacteria and Prostate Cancer PC-3 Cells

Scientists hypothesized that designed peptides with a wide spectrum of selective antimicrobial activity will also have anticancer activity, and tested this hypothesis with newly designed peptides.
[Molecules]
Juretić, D., Golemac, A., Strand, D. E., Chung, K., Ilić, N., Goić-Barišić, I., & Pellay, F.-X. (2020). The Spectrum of Design Solutions for Improving the Activity-Selectivity Product of Peptide Antibiotics against Multidrug-Resistant Bacteria and Prostate Cancer PC-3 Cells. Molecules, 25(15), 3526. https://doi.org/10.3390/molecules25153526 Cite
Full Article

Continue reading “The Spectrum of Design Solutions for Improving the Activity-Selectivity Product of Peptide Antibiotics against Multidrug-Resistant Bacteria and Prostate Cancer PC-3 Cells”

Bookmark

No account yet? Register

0
Share

Mitochondrial Functional and Structural Impairment Is Involved in the Antitumor Activity of δ-Tocotrienol in Prostate Cancer Cells

The authors investigated whether δ-tocotrienol (δ-TT) might exert its activity by impairing mitochondrial functions. They demonstrated that, in PC3 and DU145 cells, δ-TT impairs mitochondrial respiration and structural dynamics.
[Free Radical Biology and Medicine]
Fontana, F., Raimondi, M., Marzagalli, M., Audano, M., Beretta, G., Procacci, P., Sartori, P., Mitro, N., & Limonta, P. (2020). Mitochondrial functional and structural impairment is involved in the antitumor activity of δ-tocotrienol in prostate cancer cells. Free Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2020.07.009 Cite
AbstractGraphical Abstract

Continue reading “Mitochondrial Functional and Structural Impairment Is Involved in the Antitumor Activity of δ-Tocotrienol in Prostate Cancer Cells”

Bookmark

No account yet? Register

0
Share

Combination Therapy with Androgen Receptor N‐Terminal Domain Antagonist EPI‐7170 and Enzalutamide Yields Synergistic Activity in AR‐V7‐Positive Prostate Cancer

Scientists evaluated the antitumor effect of a next‐generation analog of ralaniten as a monotherapy or in combination with enzalutamide in prostate cancer cells that express AR‐V7 that were resistant to enzalutamide.
[Molecular Oncology]
Hirayama, Y., Tam, T., Jian, K., Andersen, R. J., & Sadar, M. D. (n.d.). Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Molecular Oncology, n/a(n/a). https://doi.org/10.1002/1878-0261.12770 Cite
Abstract

Continue reading “Combination Therapy with Androgen Receptor N‐Terminal Domain Antagonist EPI‐7170 and Enzalutamide Yields Synergistic Activity in AR‐V7‐Positive Prostate Cancer”

Bookmark

No account yet? Register

0
Share

Cytoprotective Autophagy Induction by Withaferin A in Prostate Cancer Cells Involves GABARAPL1

Researchers confirmed autophagy induction by withaferin A (WA) treatment by transmission electron microscopy using three prostate cancer cell lines. Fourteen common genes altered by 8‐ and 16‐hour exposure to WA were identified from human autophagy PCR array and these results were consistent with the RNA‐seq data.
[Molecular Carcinogenesis]
Hahm, E.-R., & Singh, S. V. (n.d.). Cytoprotective autophagy induction by withaferin A in prostate cancer cells involves GABARAPL1. Molecular Carcinogenesis, n/a(n/a). https://doi.org/10.1002/mc.23240 Cite
Abstract

Continue reading “Cytoprotective Autophagy Induction by Withaferin A in Prostate Cancer Cells Involves GABARAPL1”

Bookmark

No account yet? Register

0
Share

Mitoxantrone Triggers Immunogenic Prostate Cancer Cell Death via p53-Dependent PERK Expression

Immunogenic cell death was determined by assessing the release of damage-associated molecular patterns in the prostate cancer-derived cell lines LNCaP, 22RV1 and PC-3.
[Cellular Oncology]
Abstract

Continue reading “Mitoxantrone Triggers Immunogenic Prostate Cancer Cell Death via p53-Dependent PERK Expression”

Bookmark

No account yet? Register

0
Share

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer

The authors examined the potential of natural AKR1C3 inhibitors in various prostate cancer cell lines and a three-dimensional co-culture spheroid model consisting of cancer cells and cancer-associated fibroblasts mimicking enzalutamide resistant prostate cancer.
[Cancers]
Kafka, M., Mayr, F., Temml, V., Möller, G., Adamski, J., Höfer, J., Schwaiger, S., Heidegger, I., Matuszczak, B., Schuster, D., Klocker, H., Bektic, J., Stuppner, H., & Eder, I. E. (2020). Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer. Cancers, 12(8), 2092. https://doi.org/10.3390/cancers12082092 Cite
Full Article

Continue reading “Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer”

Bookmark

No account yet? Register

0
Share
Share